Hypoxia modulated gene expression: Angiogenesis, metastasis and therapeutic exploitation

European Journal of Cancer

Volumn 36, Issue 13, 2000, Pages 1649-1660

  Dachs, G U ^a   Tozer, G M ^a  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

Gene therapy; Hypoxia inducible factor 1; Nitric oxide synthase; Vascular endothelial growth factor

Indexed keywords

ANGIOGENIC FACTOR; ANTINEOPLASTIC AGENT; CHAPERONE; CYCLOPHOSPHAMIDE; CYTOKINE; ENDOTHELIAL CELL GROWTH FACTOR; FLUCYTOSINE; FLUOROURACIL; GLUCOSE TRANSPORTER; MATRIX METALLOPROTEINASE; METALLOPROTEINASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; THYMIDINE PHOSPHORYLASE; TISSUE INHIBITOR OF METALLOPROTEINASE; TRANSCRIPTION FACTOR; VASCULOTROPIN;

ANGIOGENESIS; BREAST CANCER; CARCINOGENESIS; GENE CONTROL; GENE EXPRESSION; GENE THERAPY; HUMAN; HYPOXIA; METASTASIS; PRIORITY JOURNAL; REVIEW; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

CELL HYPOXIA; DNA-BINDING PROTEINS; ENDOTHELIAL GROWTH FACTORS; GENE THERAPY; GENES, P53; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LYMPHOKINES; MATRIX METALLOPROTEINASES; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NITRIC OXIDE SYNTHASE; NUCLEAR PROTEINS; TRANSCRIPTION FACTORS; URINARY PLASMINOGEN ACTIVATOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0033867776     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(00)00159-3     Document Type: Article

References (156)

1. Vaupel, P. and Kelleher, D. K. Tumour Hypoxia: Pathophysiology, Clinical Significance and Therapeutic Perspectives. Stuttgart, Wissenschaftliche Verlagsgesellschaft mbH, 1999.
2. Vaupel, P. W. Blood Flow, Oxygenation, Tissue pH Distribution and Bioenergetic Status of Tumors. Berlin, Ernst Schering Research Foundation, 1994.
3. Brizel D.M., Sibley G.S., Prosnitz L.R., Scher R.L., Dewhirst M.W. Tumour hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int. J. Radiat. Oncol. Biol. Phys. 38:1997;285-289.
4. Dunst J., Feldmann H.J., Becker A., Stadler P., Haensgen G., Molls M. Oxygenation of human tumors. the Munich/Halle experience Vaupel P., Kelleher D.K. Tumour Hypoxia: Pathophysiology, Clinical Significance and Therapeutic Perspectives. 1999;Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart.
5. Lartigau E., Le Ridant A.M., Lambin P.et al. Oxygenation of head and neck tumours. Cancer. 71:1993;2319-2325.
6. Nordsmark M., Bentzen S.M., Overgaard J. Measurement of human tumor oxygenation status by a polarographic needle electrode. An analysis of inter- and intratumor heterogeneity. Acta. Oncol. 33:1994;383-389.
7. 2 tension measurements Cancer Res. 51:1991;6098-6102.
8. Lartigau E., Vitu L., Haie-Meder C.et al. Feasibility of measuring oxygen tension in uterine cervix carcinoma. Eur. J. Cancer. 28A:1992;1354-1357.
9. 2) in metastatic melanoma. Melanoma Res. 7:1997;400-406.
10. Chaplin D.J., Olive P.L., Durand R.E. Intermittent blood flow in a murine tumor. radiobiological effects Cancer Res. 47:1987;597-601.
11. Chaplin D.J., Hill S.A. Temporal heterogeneity in microregional erythrocyte flux in experimental solid tumours. Br. J. Cancer. 71:1995;1210-1213.
12. Vaupel P. Oxygenation of human tumors. Strahlenther. Oncol. 166:1990;377-386.
13. Mueller-Klieser W., Vaupel P., Manz R. Intracapillary oxyhemoglobin saturation of malignant tumors in humans. Int. J. Radiat. Oncol. Biol. Phys. 7:1981;1397-1404.
14. Brizel D.M. Human tumor oxygenation. the Duke University Medical Center experience Vaupel P., Kelleher D.K. Tumour Hypoxia: Pathophysiology, Clinical Significance and Therapeutic Perspectives. 1999;Stuttgart, Wissenschaftliche Verlagsgesellschaft mbH.
15. Nordsmark M., Overgaard J. Oxygenation of human tumors. the Aarhus experience Vaupel P., Kelleher D.K. Tumour Hypoxia: Pathophysiology, Clinical Significance and Therapeutic Perspectives. 1999;StuttgartWissenschaftliche Verlagsgesellschaft mbH, Stuttgart.
16. Overgaard J. Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors. Oncol. Res. 6:1994;509-518.
17. Lee D.J., Moini M., Giuliano J., Westra W.H. Hypoxic sensitizer and cytotoxin for head and neck cancer. Ann. Acad. Med. Singapore. 25:1996;397-404.
18. Hoeckel M., Schlenger K., Aral B., Mitze M., Schaeffer U., Vaupel P. Association between tumour hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 56:1996;4509-4515.
19. Brizel D.M., Scully S.P., Harrelson J.M.et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res. 56:1996;941-943.
20. Nordsmark M., Keller J., Hoyer M., Nielson O.S., Jensen O.M., Overgaard J. Hypoxia in human soft tissue sarcomas is associated with poor survival. Radiother. Oncol. 48(Suppl. 1):1998;S162.
21. Fyles A.W., Milosevic M., Wong R.et al. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother. Oncol. 48:1998;149-156.
22. Hoeckel M., Schlenger K., Hoeckel S., Vaupel P. Hypoxic cervical cancers with low apoptotic index are highly aggressive. Cancer Res. 59:1999;4525-4528.
23. Sundfor K., Lyng H., Rofstad E.K. Tumour hypoxia and vascular density as predictors of metastasis in squamous cell carcinoma of the uterine cervix. Br. J. Cancer. 78:1998;822-827.
24. Cuvier C., Jang A., Hill R.P. Exposure to hypoxia, glucose starvation and acidosis. Effect on invasive capacity of murine tumor cells and correlation with cathepsin (L+B) secretion Clin. Exp. Metastasis. 15:1997;19-25.
25. Walenta S., Salameh A., Lyng H.et al. Correlation of high lactate levels in head and neck tumors with incidence of metastasis. Am. J. Pathol. 150:1997;409-415.
26. Weidner N., Folkman J. Tumoral vascularity as a prognostic factor in cancer. DeVita V.T. Important Advances in Oncology. 1996;167-190 Lippincott-Raven, Philadelphia.
27. Huang L.E., Arany Z., Livingston D.M.et al. Activation of hypoxia inducible transcription factor depends primarily upon redox-sensitive stabilization of its alpha subunit. J. Biol. Chem. 271:1996;32253-32259.
28. Ausserer W.A., Bourrat-Floeck B., Green C.J.et al. Regulation of c-jun expression during hypoxic and low-glucose stress. Mol. Cell. Biol. 14:1994;5032-5042.
29. Koong A.C., Chen E.Y., Giaccia A.J. Hypoxia causes the activation of nuclear factor κB through phosphorylation of IκBα on tyrosine residues. Cancer Res. 54:1994;1425-1430.
30. Graeber T.G., Peterson J.F., Tsai M.et al. Hypoxia induces accumulation of p53 protein, but activation of a G1-phase checkpoint by low oxygen conditions is independent of p53 status. Mol. Cell. Biol. 14:1994;6264-6277.
31. Goldberg M.A., Gaut C.C., Bunn H.F. Erythropoietin mRNA levels are governed by both the rate of gene transcription and posttranscriptional events. Blood. 77:1991;271.
32. Madan A., Curtin P.T. A 24-base-pair sequence 3′ to the human erythropoietin gene contains a hypoxia-responsive transcriptional enhancer. Proc. Natl. Acad. Sci. USA. 90:1993;3928-3932.
33. Shweiki D., Itin A., Soffer D.et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 359:1992;843-845.
34. Shima D.T., Deutsch U., D'Amore P.A. Hypoxic induction of vascular endothelial growth factor (VEGF) in human epithelial cells is mediated by increases in mRNA stability. FEBS. Lett. 370:1995;203-208.
35. Levy N.S., Goldberg M.A., Levy A.P. Sequencing of the human vascular endothelial growth factor (VEGF) 3′ untranslated region (UTR). conservation of five hypoxia-inducible RNA-protein binding sites Biochem. Biophys. Acta. 1352:1997;167-173.
36. Griffiths L., Dachs G.U., Bicknell R.et al. The influence of oxygen tension and pH on the expression of platelet derived endothelial cell growth factor/thymidine phosphorylase in human breast tumour cells grown in vitro and in vivo. Cancer Res. 57:1997;570-572.
37. Shaul P.W., North A.J., Brannon T.S.et al. Prolonged in vivo hypoxia enhances nitric oxide synthase type I and type III gene expression in adult rat lung. Am. J. Respir. Cell. Mol. Biol. 13:1995;167-174.
38. McQuillan L.P., Leung G.K., Marsden P.A., Kostyk S.K., Kourembanas S. Hypoxia inhibits expression of eNOS via transcriptional and posttranslational mechanisms. Am. J. Physiol. 267:1994;H1921-H1927.
39. Stark W.W., Wasserloos K., Modzelewski R.et al. Hypoxia stimulates NFκB mediated iNOS expression in tumour endothelial cells. Mol. Biol. Cell. 6:1995;438.
40. Melillo G., Musso T., Sica A., Taylor L.S., Cox G.W., Varesio L. A hypoxia-responsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promoter. J. Exp. Med. 182:1995;1683-1693.
41. Melillo G., Taylor L.S., Brooks A.et al. Functional requirement of the hypoxia responsive element in the activation of the inducible nitric oxide synthase promoter by the iron chelator desferrioxamine. J. Biol. Chem. 272:1997;12236-12243.
42. Hu J., Disher D.J., Bishopric N.H., Webster K.A. Hypoxia regulates expression of the endothelin-1 gene through a proximal hypoxia-inducible factor-1 binding site on the antisense strand. Biochem. Biophys. Res. Comm. 245:1998;894-899.
43. Bunn H.F., Poyton R.O. Oxygen sensing and molecular adaptation to hypoxia. Physiol. Rev. 76:1996;839-885.
44. Dachs G.U., Chaplin D.J. Microenvironmental control of gene expression. implications for tumour angiogenesis, progression, and metastasis Semin. Radiat. Oncol. 8:1998;208-216.
45. Beck I., Weinmann R., Caro J. Characterisation of hypoxia-responsive enhancer in the human erythropoietin gene shows presence of hypoxia-inducible 120-kD-a nuclear DNA-binding protein in erythropoietin-producing and nonproducing cells. Blood. 82:1993;704-711.
46. Wang G.L., Semenza G.L. Characterization of hypoxia-inducible factor-1 and regulation of DNA-binding activity by hypoxia. J. Biol. Chem. 268:1993;21513-21518.
47. 2 tension. Proc. Natl. Acad. Sci. USA. 92:1995;5510-5514.
48. Wang G.L., Semenza G.L. General involvement of hypoxia-inducible factor-1 in transcriptional response to hypoxia. Proc. Natl. Acad. Sci. USA. 90:1993;4304-4308.
49. Maxwell P.H., Pugh C.W., Ratcliffe P.J. Inducible operation of the erythopoietin 3′ enhancer in multiple cell lines. evidence for a widespread oxygen sensing mechanism Proc. Natl. Acad. Sci. USA. 90:1993;2423-2427.
50. Wiener C.M., Booth G., Semenza G.L. In vivo expression of messenger RNAs encoding hypoxia inducible factor-1. Biochem. Biophys. Res. Commun. 225:1996;485-488.
51. Zhong H., DeMarzo A.M., Laughner E.et al. Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastasis. Cancer Res. 59:1999;5830-5835.
52. Zhong H., Agani F., Baccala A.A.et al. Increased expression of hypoxia inducible factor 1α in rat and human prostate cancer. Cancer Res. 58:1998;5280-5284.
53. Gradin K., McGuire J., Wenger R.H.et al. Functional interference between hypoxia and dioxin signal transduction pathways- competition for recruitment of the ARNT transcription factor. Mol. Cell. Biol. 16:1996;5221-5231.
54. Arany Z., Huang L.E., Eckner R.et al. An essential role for p300/CBP in the cellular response to hypoxia. Proc. Natl. Acad. Sci. USA. 93:1996;12969-12973.
55. Maxwell P.H., Wiesener M.S., Chang G.W.et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 399:1999;271-275.
56. Ebert B.L., Bunn H.F. Regulation of transcription by hypoxia requires a multiprotein complex that includes hypoxia-inducible factor 1, and adjacent transcription factor, and p300/CREB binding protein. Mol. Cell. Biol. 18:1998;4089-4096.
57. Kallio P.J., Okamoto K., O'Brien S.et al. Signal transduction in hypoxic cells: inducible nuclear translocation and recruitment of the CBP/p300 coactivator by the hypoxia-inducible factor 1α EMBO J. 17:1998;6573-6586.
58. Minet E., Mottet D., Michel G.et al. Hypoxia-induced activation of HIF-1, role of HIF-1α-Hsp90 interaction. FEBS. Lett. 460:1999;251-256.
59. Levy A.P., Levy N.S., Goldberg M.A. Hypoxia-inducible protein binding to vascular endothelial growth factor mRNA and its modulation by the von Hippel Lindau protein. J. Biol. Chem. 271:1996;25492-25497.
60. ThrashBingham C.A., Tartof K.D. aHIF. a natural antisense transcript overexpressed in human renal cancer and during hypoxia J. Natl. Cancer Inst. 91:1999;143-151.
61. Carrero P., Okamoto K., Coumailleau P., O'Brien S., Tanaka H., Poellinger L. Redox-regulated recruitment of the transcriptional coactivators CREB-binding protein and SRC-1 to hypoxia-inducible factor-1α Mol. Cell. Biol. 20:2000;402-415.
62. Tian H., McKnight S.L., Russell D.W. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev. 11:1997;72-82.
63. Ema M., Taya S., Yokotani N.et al. A novel bHLH-PAS factor with close sequence similarity to hypoxia inducible factor1 alpha regulates VEGF expression and is potentially involved in lung and vascular development. Proc. Natl. Acad. Sci. USA. 94:1997;4273-4278.
64. 2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc. Natl. Acad. Sci. USA. 95:1998;7987-7992.
65. Kallio P.J., Wilson W.J., O'Brien S., Makino Y., Poellinger L. Regulation of the hypoxia-inducible factor-1α by the ubiquitin-proteasome pathway. J. Biol. Chem. 274:1999;6519-6525.
66. Chilov D., Camenish G., Kvietikova I., Ziegler U., Gassmann M., Wenger R.H. Induction and nuclear translocation of hypoxia-inducible factor-1 (HIF-1). heterodimerisation with ARNT is not necessary for nuclear accumulation of HIF-1α J. Cell Sci. 112:1999;1203-1212.
67. Maxwell P.H., Dachs G.U., Gleadle J.M.et al. Hypoxia inducible factor-1 modulates gene expression in solid tumours and influences both angiogenesis and tumour growth. Proc. Natl. Acad. Sci. USA. 94:1997;8104-8109.
68. Stratford I.J., Patterson A.V., Dachs G.U., Telfer B., Williams K.J. Hypoxia-mediated gene expression. Vaupel P., Kelleher D.K. Tumour Hypoxia. 1999;107-113 Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart.
69. Williams KJ, Telfer B, Dachs GU, et al. Potentiation of radiosensitivity in tumours lacking HIF-1β. 11th Interntl Congress Rad Res, Dublin 1999, 232.
70. Carmeliet P., Dor Y., Herbert J.M.et al. Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumor angiogenesis. Nature. 394:1998;485-490.
71. Wenger R.H., Kvietikova I., Rolfs A., Camenish G., Gassmann M. Oxygen-regulated erythropoietin expression is dependent on a CpG methylation-free hypoxia-inducible factor-1 DNA-binding site. Eur. J. Biochem. 253:1998;771-777.
72. Graeber T.G., Osmanian C., Jacks T.et al. Hypoxia mediated selection of cells with diminished apoptotic potential in solid tumours. Nature. 379:1996;88-91.
73. Blagosklonny M.V., An W.G., Romanova L.Y., Trepel J., Fojo T., Neckers L. p53 inhibits hypoxia-inducible factor-stimulated transcription. J. Biol. Chem. 273:1998;1195-11998.
74. Wenger R.H., Camenish G., Desbaillets I., Chilov D., Gassmann M. Upregulation of hypoxia-inducible factor 1α is not sufficient for hypoxic/anoxic p53 induction. Cancer Res. 58:1998;5678-5680.
75. Ravi R., Mookerjee B., Bhujwalla Z.M.et al. Regulation of tumour angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α Gene Dev. 14:2000;34-44.
76. Plate K.H., Breier G., Weich H.A.et al. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature. 359:1992;845-848.
77. Plate K.H., Breier G., Millauer B.et al. Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumour angiogenesis. Cancer Res. 53:1993;5822-5827.
78. Salven P., Heikkila P., Joensuu H. Enhanced expression of vascular endothelial growth factor in metastatic melanoma. Br. J. Cancer. 76:1997;930-934.
79. Wong M.P., Cheung N., Yuen S.T., Leung S.Y., Chung L.P. Vascular endothelial growth factor is upregulated in early premalignant stage of colorectal tumour progression. Int. J. Cancer. 81:1999;845-850.
80. Salven P., Heikkila P., Anttonen A., Kajanti M., Joensuu H. Vascular endothelial growth factor in squamous head and neck carcinoma. expression and prognostic significance Modern Pathol. 10:1997;1128-1133.
81. ElAssal O.N., Yamanoi A., Soda Y.et al. Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver. possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver Hepatology. 27:1998;1554-1562.
82. Maniwa Y., Okada M., Ishii N., Kiyooka K. Vascular endothelial growth factor increased by pulmonary surgery accelerates the growth of micrometastases in metastatic lung cancer. Chest. 114:1998;1668-1675.
83. Matsuura A., Yamochi W., Hirata K., Kawashima S., Yokoyama M. Stimulatory interaction between vascular endothelial growth factor and endothelin-1 on each gene expression. Hypertension. 32:1998;89-95.
84. Parliament M.B., Allalunis-Turner M.J., Franko A.J.et al. Vascular endothelial growth factor expression is independent of hypoxia in human malignant glioma spheroids and tumours. Br. J. Cancer. 82:2000;635-641.
85. Raleigh J.A., CalkinsAdams D.P., Rinker L.H.et al. Hypoxia and vascular endothelial growth factor expression in human squamous cell carcinomas using pimonidazole as a hypoxia marker. Cancer Res. 58:1998;3765-3768.
86. Raleigh J.A., Chou S.C., CalkinsAdams D.P., Ballenger C.A., Novotny D.B., Varia M.A. A clinical study of hypoxia and metallothionein protein expression in squamous cell carcinomas. Clin. Cancer Res. 6:2000;855-862.
87. Minchenko A., Salceda S., Bauer T.et al. Hypoxia regulatory elements of the human vascular endothelial growth factor gene. Cell. Mol. Biol. Res. 40:1994;35-39.
88. Ladoux A., Frelin C. Hypoxia is a strong inducer of vascular endothelial growth factor mRNA expression in the heart. Biochem. Biophys. Res. Commun. 195:1993;1005-1010.
89. Damert A., Machein M., Breier G.et al. Upregulation of vascular endothelial growth factor expression in a rat glioma is conferred by two distinct hypoxia driven mechanisms. Cancer Res. 57:1997;3860-3864.
90. Levy A.P., Levy N.S., Goldberg M.A. Posttranscriptional regulation of vascular endothelial growth factor by hypoxia. J. Biol. Chem. 271:1996;2746-2753.
91. Levy N.S., Chung S.M., Furneaux H., Levy A.P. Hypoxic stabilization of vascular endothelial growth factor mRNA by the RNA-binding protein HuR. J. Biol. Chem. 273:1998;6417-6423.
92. Dibbens J.A., Miller D.L., Damert A., Risau W., Vada M.A., Goodall G.J. Hypoxic regulation of vascular endothelial growth factor mRNA stability requires the cooperation of RNA elements. Mol. Biol. Cell. 10:1999;907-919.
93. Stein I., Itin A., Einat P., Skaliter R., Grossmann Z., Keshet E. Translation of vascular endothelial growth factor mRNA by internal ribosome entry. implications for translation under hypoxia Mol. Cell. Biol. 18:1998;3112-3119.
94. Akiri G., Nahari D., Finkelstein Y., Le S.Y., ElroyStein O., Levi B.Z. Regulation of vascular endothelial growth factor (VEGF) expression is mediated by internal initiation of translation and alternative initiation of transcription. Oncogene. 17:1998;227-236.
95. Miller D.L., Dibbens J.A., Damert A., Risau W., Vadas M.A., Goodall G.J. The vascular endothelial growth factor mRNA contains an internal ribosome entry site. FEBS. Lett. 434:1998;417-420.
96. Kitazono M., Takebayashi Y., Ishitsuka K.et al. Prevention of hypoxia-induced apoptosis by the angiogenic factor thymidine phosphorylase. Biochem. Biophys. Res. Commun. 253:1998;797-803.
97. Griffiths L., Stratford I.J. The influence of elevated levels of platelet derived endothelial growth factor thymidine phosphorylase on tumorigenicity, tumour growth and oxygenation. Int. J. Radiat. Oncol. Biol. Phys. 42:1998;877-883.
98. Koukourakis M.I., Giatromanolaki A., O'Byrne K.J.et al. Platelet derived endothelial cell growth factor expression correlates with tumour angiogenesis and prognosis in non-small cell lung cancer. Br. J. Cancer. 75:1997;477-481.
99. Relf M., LeJeune S., Scott P.A.E.et al. Expression of the angiogenic factors vascular endothelial growth factor, acidic and basic fibroblast growth factor, tumour growth factor β-1, platelet derived endothelial cell growth factor, placenta growth factor and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res. 57:1997;963-969.
100. Tozer G.M., Everett S.A. Nitric oxide in tumour biology and cancer therapy. Part 1: physiological aspects. Clin. Oncol. 9:1997;282-293.
101. Tozer G.M., Everett S.A. Nitric oxide in tumour biology and cancer therapy. Part 2: Therapeutic implications. Clin. Oncol. 9:1997;357-364.
102. Verovski B., Bols B., Van den Berg D., Storme G. Mechanism of production and radiosensitizing effect of nitric oxide generated by chemical donors and nitric oxide synthase. Proc. Am. Assoc. Cancer Res. 38:1997;43.
103. Moro M.A., De-Alba J., Leza J.C.et al. Neuronal expression of inducible nitric oxide synthase after oxygen and glucose deprivation in rat forebrain slices. Eur. J. Neurosci. 10:1998;445-456.
104. Palmer L.A., Semenza G.L., Stoler M.H., Johns R.A. Hypoxia induces type II NOS gene expression in pulmonary artery endothelial cells via HIF-1. Am. J. Physiol. 274:1998;L212-L219.
105. Arnet U., McMillan A., Dinerman J., Ballermann B., Lowenstein C. Regulation of endothelial nitric-oxide synthase during hypoxia. J. Biol. Chem. 271:1996;15069-15073.
106. Justice J.M., Tanner M.A., Myers P.R. Endothelial cell regulation of nitric oxide production during hypoxia in coronary microvessels and epicardial arteries. J. Cell. Physiol. 182:2000;359-365.
107. Liao J.K., Zulueta J.J., Yu F-S., Peng H-B., Cote C.G., Hassoun P.M. Regulation of bovine endothelial constitutive nitric oxide synthase by oxygen. J. Clin. Invest. 96:1995;2661-2666.
108. Phelan M., Faller D. Hypoxia decreases constitutive nitric oxide synthase transcript and protein in cultured endothelial cells. J. Cell. Physiol. 167:1996;469-476.
109. Gess B., Schricker K., Pfeifer M., Kurtz A. Acute hypoxia upregulates NOS gene expression in rats. Am. J. Physiol. 273:1997;R905-R910.
110. Faller D.V. Endothelial responses to hypoxic stress. Clin. Exp. Pharmacol. Physiol. 26:1999;74-84.
111. Kim N., Vardi Y., Padma-Nathan H., Daley J., Goldstein I., Saenz de Tejada I. Oxygen tension regulates the nitric oxide pathway. physiological role in penile erection J. Clin. Invest. 91:1993;437-442.
112. Abu-Soud H., Rousseau D.L., Stuehr D.J. Nitric oxide binding to the heme of neuronal nitric-oxide synthase links its activity to changes in oxygen tension. J. Biol. Chem. 271:1996;32515-32518.
113. Thomsen L.L., Lawton F.G., Knowles R.G., Beesley J.E., Riveros-Moreno V., Moncada S. Nitric oxide synthase activity in human gynecological cancer. Cancer Res. 54:1994;1352-1354.
114. Cobbs C.S., Brenman J.E., Aldape K.D., Bredt D.S., Israel M.A. Expression of nitric oxide synthase in human central nervous system tumors. Cancer Res. 55:1995;727-730.
115. Thomsen L.L., Miles D.W., Happerfield L., Bobrow L.G., Knowles R.G., Moncada S. Nitric oxide synthase activity in human breast cancer. Br. J. Cancer. 72:1995;41-44.
116. Kennovin G.D., Hirst D.G., Stratford M.R.L., Flitney F.W. Inducible nitric oxide synthase is expressed in tumour-associated vasculature. inhibition retards tumour growth in vivo Moncada S., Feelisch M., Busse R., Higgs E.A. The Biology of Nitric Oxide 4. Enzymology, Biochemistry and Immunology. 1994;473-479 Portland Press, London.
117. Orucevic A., Lala P.K. NG-nitro-L-arginine methyl ester, an inhibitor of nitric oxide synthesis ameliorates interleukin 2-induced capillary leakage and reduces tumour growth in adenocarcinoma-bearing mice. Br. J. Cancer. 73:1996;189-196.
118. Jenkins D.C., Charles I.G., Thomsen L.L.et al. Roles of nitric oxide in tumour growth. Proc. Natl. Acad. Sci. USA. 92:1995;4392-4396.
119. Xie K., Huang S., Dong Z.et al. Transfection with the inducible nitric oxide synthase gene suppresses tumorigenicity and abrogates metastasis by K-1735 murine melanoma cells. J. Exp. Med. 181:1995;1333-1343.
120. Shi Q., Huang S., Jiang W., Kutach L.S., Ananthaswamy H.N. Direct correlation between nitric oxide synthase II inducibility and metastatic ability of UV-2237 murine fibrosarcoma cells carrying mutant p53. Cancer Res. 59:1999;2072-2075.
121. Lala P.K., Orucevic A. Role of nitric oxide in tumor progression. lessons from experimental tumors Cancer Metastasis Rev. 17:1998;91-106.
122. Rocha M., Krüger A., Van Rooijen N., Schirrmacher V., Umansky V. Liver endothelial cells participate in T-cell-dependent host resistance to lymphoma metastasis by production of nitric oxide in vivo. Int. J. Cancer. 63:1995;405-411.
123. Poluha W., Harrington K.S., Lachyankar M.B., Schonhoff C.M., Crosbie N.E., Ross A.H. A novel NGF-regulated pathway involving nitric oxide, p53 and p21WAF1 controls differentiation of PC12 cells. Proc. Am. Assoc. Cancer Res. 39:1997;498.
124. Ambs S., Merriam W.G., Bennet W.P.et al. Interaction of nitric oxide and p53 in tumor growth. a putative model for clonal selection of mutant p53 cells Proc. Am. Assoc. Cancer Res. 39:1997;273.
125. Andrade S.P., Hart I.R., Piper P.J. Inhibitors of nitric oxide synthase selectively reduce flow in tumour-associated neovasculature. Br. J. Pharmacol. 107:1992;1092-1095.
126. Meyer R.E., Shan S., DeAngelo J.et al. Nitric oxide synthase inhibition irreversibly decreases perfusion in the R3230Ac rat mammary adenocarcinoma. Br. J. Cancer. 71:1995;1169-1174.
127. Tozer G.M., Prise V.E., Chaplin D.J. Inhibition of nitric oxide synthase induces a selective reduction in tumor blood flow that is reversible with L-arginine. Cancer Res. 57:1997;948-955.
128. Wood P.J., Sansom J.M., Butler S.A.et al. Induction of hypoxia in experimental murine tumors by the nitric oxide synthase inhibitor, NG-nitro-L-arginine. Cancer Res. 54:1994;6458-6463.
129. Lee P.C., Salyapongse A.N., Bragdon G.A.et al. Impaired wound healing and angiogenesis in eNOS-deficient mice. Am. J. Physiol. 277:1999;H1600-H1608.
130. Jadeski L.C., Lala P.K. Nitric oxide synthase inhibition by N(G)-nitro-L-arginine methyl ester inhibits tumor-induced angiogenesis in mammary tumors. Am. J. Pathol. 155:1999;1381-1390.
131. Papapetropoulos A., Garcia-Cardena G., Madri J.A., Sessa W.C. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J. Clin. Invest. 100:1997;3131-3139.
132. Ziche M., Morbidelli L., Choudhuri R.et al. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J. Clin. Invest. 99:1997;2625-2634.
133. Shizukuda Y., Tang S., Yokota R., Ware J.A. Vascular endothelial growth factor-induced endothelial cell migration and proliferation depend on a nitric oxide-mediated decrease in protein kinase C delta activity. Circ. Res. 85:1999;247-256.
134. Murohara T., Witzenbichler B., Spyridopoulos I.et al. Role of endothelial nitric oxide synthase in endothelial cell migration. Arterioscler. Thromb. Vasc. Biol. 19:1999;1156-1161.
135. He H., Venema V.J., Gu X., Venema R.C., Marrero M.B., Caldwell R.B. Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through flk-1/KDR activation of c-SRC. J. Biol. Chem. 274:1999;25130-25135.
136. Kimura H., Weisz A., Kurashima Y.et al. Hypoxia response element of the human vascular endothelial growth factor gene mediates transcription regulated by nitric oxide. control of hypoxia-inducible factor-1 activity by nitric oxide Blood. 95:2000;189-197.
137. Liu Y.X., Christou H., Morita T., Laughner E., Semenza G.L., Kourembanas S. Carbon monoxide and nitric oxide suppress the hypoxic induction of vascular endothelial growth factor gene via the 5′enhancer. J. Biol. Chem. 273:1998;15257-15262.
138. Eyssen-Hernandez R., Ladoux A., Frelin C. Differential regulation of cardiac heme oxygenase-1 and vascular endothelial growth factor mRNA expressions by hemin, heavy metals, heat shock and anoxia. FEBS. Lett. 382:1996;229-233.
139. Motterlini R., Foresti R., Intaglietta M., Winslow R.M. NO-mediated activation of heme oxygenase. endogenous cytoprotection against oxidative stress to endothelium Am. J. Physiol. 270:1996;H107-H114.
140. Takahashi K., Hara E., Suzuki H., Sasano H., Shibara S. Expression of heme oxygenase isozyme mRNAs in the human brain and the induction of heme oxygenase-1 by nitric oxide donors. J. Neurochem. 67:1996;482-489.
141. Tozer G.M., Prise V.E., Motterlini R., Poole B.A., Wilson J., Chaplin D.J. The comparative effects of the NOS inhibitor, Nw-nitro-L-arginine, and the haemoxygenase inhibitor, zinc protoporphyrin IX, on tumour blood flow. Int. J. Radiat. Oncol. Biol. Phys. 42:1998;849-853.
142. Jang A., Hill R.P. An examination of the effects of hypoxia, acidosis, and glucose starvation on the expression of metastasis-associated genes in murine tumour cells. Clin. Exp. Metastasis. 15:1997;469-483.
143. Orphanides C., Fine L.G., Norman J.T. Hypoxia stimulates proximal tubular cell matrix production via a TGFβ-independent mechanism. Kidney Int. 52:1997;637-647.
144. Ishigaki S., Toi M., Ueno T.et al. Significance of membrane type 1 matrix metalloproteinase expression in breast cancer. Jpn. J. Cancer Res. 90:1999;516-522.
145. Himelstein B.P., Koch C.J. Studies of type IV collagenase regulation by hypoxia. Cancer Lett. 124:1998;127-133.
146. Graham C.H., Forsdike J., Fitzgerald C.J., Macdonald Goodfellow S. Hypoxia-mediated stimulation of carcinoma cell invasiveness via upregulation of urokinase receptor expression. Int. J. Cancer. 80:1999;617-623.
147. Dachs GU, Coralli C, Hart SL, Tozer GM. Gene delivery to hypoxic cells in vitro. Br J Cancer 2000, 83, in press.
148. Dachs G.U., Patterson A.V., Firth J.D.et al. Targeting gene expression to hypoxic tumour cells. Nature Med. 3:1997;515-520.
149. Binley K., Iqball S., Kingsman A., Kingsman S., Naylor S. An adenoviral vector regulated by hypoxia for the treatment of ischemic disease and cancer. Gene Ther. 6:1999;1721-1727.
150. Boast K., Binley K., Iqball S.et al. Characterization of physiologically regulated vectors for the treatment of ischemic disease. Human Gene Ther. 10:1999;2197-2208.
151. Shibata T., Giaccia A.J., Brown J.M. Development of a hypoxia-responsive vector for tumour-specific gene therapy. Gene Ther. 7:2000;493-498.
152. Bridgewater J.A., Springer C.J., Knox R.J., Minton N.P., Michael N.P., Collins M.K. Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954. Eur. J. Cancer. 31A:1995;2326-2370.
153. Patterson A.V., Harris A.L. Molecular chemotherapy for breast cancer. Drugs Aging. 14:1999;75-90.
154. Greco O., Dachs G.U., Wardman P., Folkes L.K., Chaplin D.J. Development of an enzyme prodrug combination for gene therapy of cancer. Proc. Am. Assoc. Cancer Res. 40:1999;478.
155. Greco O., Tozer G.M., Dachs G.U. Utilising horseradish peroxidase for hypoxia-induced gene therapy. Proc. Am. Assoc. Cancer Res. 41:2000;733.
156. Griffiths L., Binley K., Iqball S.et al. The macrophage- a novel system to deliver gene therapy to pathological hypoxia. Gene Ther. 7:2000;255-262.